Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Persistence of Nimenrix vs Mencevax ACWY in Adolescents
NCT00390143Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2007
- Primary completion
- May 2009
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of meningococcal group A, C, W135 and Y conjugate vaccine in meningococcal infection (2 arms), sponsored by GSK. Primary endpoints: Meningococcal serum bactericidal antibody titres at Month 42, Anti-meningococcal polysaccharide concentrations at Month 42 and 1 more. Started Feb 2007; status: completed.
02
Drugs
meningococcal group A, C, W135 and Y conjugate vaccine
03
Conditions
meningococcal infection
Beyond the preview
Go deeper on NCT00390143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00390143.